Regeneron Pharmaceuticals Inc $296.74

down -3.40


17/4/2014 08:10 PM  |  NASDAQ : REGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get REGN Trend Analysis - it has outperformed the S&P 500 by 19%

Partner Headlines

  1. UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals ...

    Benzinga
  2. Benzinga's Top Initiations

    Benzinga
  3. Top 40 Upcoming Earnings Releases

    Benzinga
  4. Biotechs Struggling To Find A Bottom

    Benzinga
  5. Nasdaq Sheds 1% As China Growth Names, Biotechs Fall Hard

    IBD
  6. S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq

    IBD
  7. Cholesterol drug meets goal

    IBD
  8. Nasdaq Leads Another Up Day; S&P 500 Hits All-Time High

    IBD
  9. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  10. Gilead Adds To Biotech Woes

    IBD
  11. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  12. Rebound Rally Losing More Steam; BitAuto Hangs Tough

    IBD
  13. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  14. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
  15. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  16. US Stock Futures Rise; GDP, Jobless Claims Data In Focus

    Benzinga
  17. Netflix, Other Big Cap Growth Stocks Offer Buy Points

    IBD
  18. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  19. UPDATE: Citigroup Upgrades Regeneron Pharmaceuticals

    Benzinga
  20. Regeneron falls on FDA probe

    IBD
  21. Nasdaq Lags As Stock Market Closes Lower

    IBD
  22. Early Gains Fade; E-House Breaks Out But Biotechs Stumble

    IBD
  23. Regeneron Cholesterol-Drug Worries Ding Stock

    IBD
  24. Ukraine Unrest Sparks Selling But Some Biotechs Firm Up

    IBD
  25. Regeneron CEO Sees Surge

    IBD
  26. Regeneron Pipeline Could Be The Big Story In 2014

    IBD
  27. Revenue Growth: Focus On Healthcare Stocks

    YCharts
  28. Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA

    GuruFocus
  29. Regeneron Beats With Eylea

    IBD
  30. Regeneron Longer-Term Growth Prospects Boosts Stock

    IBD
  31. Regeneron Pharmaceuticals Continue Higher Following a Mid-Day Report from ...

    Benzinga
  32. Stocks End Near Session Highs; Ligand, Regeneron Jump

    IBD
  33. Stocks Hold Near Highs In Strong Session; Regeneron Soars

    IBD
  34. Stocks Up Further At Midday; Regeneron Works On Base

    IBD
  35. Top Trending Tickers On StockTwits For February 11

    Benzinga
  36. Regeneron Q4 Beats Estimates; Guidance In Line

    IBD
  37. Earnings Scheduled For February 11, 2014

    Benzinga
  38. Regeneron drug tests upbeat

    IBD
  39. Regeneron To Guide 2014 As Eylea Continues To Shine

    IBD
  40. UPDATE: Regeneron Reports Two-Year Results from Phase 3 VISTA Trail of ...

    Benzinga
  41. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD
  42. Biotechs Still Hold Promise in 2014 and Beyond

    FoxBusiness
  43. Stocks Little Changed After Beige Book Report

    IBD
  44. Illumina Upbeat On Q4, 2014

    IBD
  45. Illumina, Regeneron, Intuitive Q4 Results Impress

    IBD
  46. REGENERON

    IBD
  47. UPDATE: Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related ...

    Benzinga
  48. UPDATE: Piper Jaffray Initiates Coverage on Regeneron Pharmaceuticals as ...

    Benzinga
  49. Stocks Higher In Afternoon; Biotech Stocks Lead Gains

    IBD
  50. US Stock Futures Flat After Record Close

    Benzinga
Trading Center